Literature DB >> 33724800

Ros3 (Lem3p/CDC50) Gene Dosage Is Implicated in Miltefosine Susceptibility in Leishmania (Viannia) braziliensis Clinical Isolates and in Leishmania (Leishmania) major.

Caroline R Espada1, Andreia Albuquerque-Wendt2,3,4, Valentín Hornillos5, Eva Gluenz2,4, Adriano C Coelho6, Silvia R B Uliana1.   

Abstract

The Ros3 protein is a component of the MT-Ros3 transporter complex, considered as the main route of miltefosine entry in Leishmania. L. braziliensis clinical isolates presenting differences in miltefosine susceptibility and uptake were previously shown to differentially express ros3. In this work, we showed that the ros3 gene copy number was increased in the isolate presenting the highest rates of miltefosine uptake and, thus, the highest susceptibility to this drug. The role of the ros3 gene dosage in miltefosine susceptibility was then investigated through a modulation of the gene copy number using two distinct approaches: through an overexpression of ros3 in a tolerant L. braziliensis clinical isolate and in L. major and by generating mono- and diallelic knockouts of this gene in L. major using clustered regularly interspaced short palindromic repeats (CRISPR) Cas9 (Cas = CRISPR-associated). Although the levels of ros3 mRNA were increased at least 40-fold in overexpressing clones, no significant reduction in the half-maximal effective concentration (EC50) for miltefosine was observed in these parasites. The partial or complete deletion of ros3 in L. major, in turn, resulted in a significant increase of 3 and 20 times, respectively, in the EC50 to miltefosine. We unequivocally showed that the ros3 copy number is one of the factors involved in the differential susceptibility and uptake of miltefosine.

Entities:  

Keywords:  CRISPR/Cas9; Leishmania braziliensis; clinical isolates; drug resistance; miltefosine; treatment

Year:  2021        PMID: 33724800     DOI: 10.1021/acsinfecdis.0c00857

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  5 in total

1.  Culture of Cutaneous Leishmania from Skin Biopsy Specimens.

Authors:  Andrea Paun
Journal:  Curr Protoc       Date:  2022-02

2.  Effective Genome Editing in Leishmania (Viannia) braziliensis Stably Expressing Cas9 and T7 RNA Polymerase.

Authors:  Caroline R Espada; José Carlos Quilles; Andreia Albuquerque-Wendt; Mario C Cruz; Tom Beneke; Lucas B Lorenzon; Eva Gluenz; Angela K Cruz; Silvia R B Uliana
Journal:  Front Cell Infect Microbiol       Date:  2021-11-10       Impact factor: 5.293

3.  Targeted Deletion of Centrin in Leishmania braziliensis Using CRISPR-Cas9-Based Editing.

Authors:  Rohit Sharma; Francys Avendaño Rangel; João Luís Reis-Cunha; Larissa Pinheiro Marques; Claudio P Figueira; Pedro B Borba; Sayonara M Viana; Tom Beneke; Daniella C Bartholomeu; Camila I de Oliveira
Journal:  Front Cell Infect Microbiol       Date:  2022-02-17       Impact factor: 5.293

Review 4.  Impact of Genetic Diversity and Genome Plasticity of Leishmania spp. in Treatment and the Search for Novel Chemotherapeutic Targets.

Authors:  Ana Maria Murta Santi; Silvane Maria Fonseca Murta
Journal:  Front Cell Infect Microbiol       Date:  2022-01-24       Impact factor: 5.293

5.  Genome deletions to overcome the directed loss of gene function in Leishmania.

Authors:  Edubiel A Alpizar-Sosa; Yasmine Kumordzi; Wenbin Wei; Phillip D Whitfield; Michael P Barrett; Paul W Denny
Journal:  Front Cell Infect Microbiol       Date:  2022-09-23       Impact factor: 6.073

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.